ITM appoints CMO

ITM Isotope Technologies Munich SE, a developer of radiopharmaceuticals, has appointed Celine Wilke as chief medical officer. She will lead clinical development and the medical teams in bringing the therapy ITM-11 toward potential market approval. ITM-11 is being developed for patients with neuroendocrine tumours, a rare form of cancer, and has delivered positive data from a Phase 3 trial. Dr Wilke joins ITM from Novartis in Basel, Switzerland where she was senior global program clinical head for prostate cancer, overseeing clinical trials for radiopharmaceutical therapies and imaging compounds. She held several leadership positions at Novartis focusing on drug development, including regulatory discussions and global NDA submissions. Dr Wilke is a board-certified physician specialised in clinical pharmacology and oncology. She obtained her medical training at the Medical School University Rostock, Germany, University Bari, Italy and California State University, US.

ITM announced the appointment on 1 April 2025.